CX Institutional Has $4.55 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• CX Institutional raised its stake in Jazz Pharmaceuticals PLC by 23.4% during the second quarter, increasing its holdings to 42,892 shares valued at approximately $4.55 million.
• Several hedge funds, including Mackenzie Financial Corp and UBS AM, have also increased their positions in Jazz Pharmaceuticals amidst significant institutional ownership, which stands at 89.14%.
• Jazz Pharmaceuticals recently faced an earnings miss for the quarter, reporting an EPS of ($8.25) compared to analyst expectations of ($5.61), despite a revenue of $1.05 billion.

CX Institutional raised its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 23.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,892 shares of the specialty pharmaceutical company's stock after purchasing an additional 8,124 shares during the quarter. CX Institutional owned approximately 0.07% of Jazz Pharmaceuticals worth $4,552,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Nuveen LLC purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at about $62,362,000. Fuller & Thaler Asset Management Inc. increased its position in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after purchasing an additional 391,660 shares during the period. Perpetual Ltd grew its holdings in Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock valued at $118,212,000 after buying an additional 357,784 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after purchasing an additional 293,360 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock valued at $43,652,000 after purchasing an additional 209,667 shares during the period. Institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price on the stock. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Truist Financial raised their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $178.67.

Jazz Pharmaceuticals Stock Down 2.2%

Shares of JAZZ traded down $2.89 during mid-day trading on Friday, reaching $128.30. The company had a trading volume of 1,488,638 shares, compared to its average volume of 719,843. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company has a market capitalization of $7.78 billion, a price-to-earnings ratio of -19.06, a price-to-earnings-growth ratio of 7.96 and a beta of 0.24. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The firm has a 50-day moving average price of $120.39 and a 200 day moving average price of $115.94.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same quarter last year, the firm posted $5.30 EPS. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director owned 429,973 shares of the company's stock, valued at $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.30% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.